Digital Microscopy Imaging in Drug Discovery and Development

2001 ◽  
Vol 7 (S2) ◽  
pp. 622-623
Author(s):  
Xiaoyou Ying ◽  
Jean Sprinkle Cavallo ◽  
Bruce McCullough
Keyword(s):  
Drug Discovery ◽  
State Of The Art ◽  
Biological Research ◽  
Digital Microscopy ◽  
Microscopy Imaging ◽  
Bioimage Informatics ◽  
Drug Discovery And Development ◽  
Subcellular Organelles ◽  
The Past ◽  
Almost All

Digital microscopy, the integration of digital and microscopy technologies, was initiated for quantitative microscopic image analysis, but it is now for almost all microscopy applications. During the past decade, with the advance of digital technologies, digital microscopy imaging is becoming an indispensable technology in drug discovery.We started establishing state-of-the-art digital microscopy imaging for drug discovery with the investigation of bioimaging applications at our US research site. Our results shown that all the top 5 bioimaging needs require computer-aided microscopy. Based on this investigation and our review of the microscopy imaging applications in the pharmaceutical industry, we determined four directions for microscopy in drug discovery: multidimensional/multimodal microscopy, digitalization, automation, and bioimage informatics.Multidimensional/multimodal microscopy imaging is required by the nature of biological research, which is fundamental in drug discovery. From genomic imaging to pathology observation, we require biological details and compound activities at the levels from subcellular organelles to organ tissues, from cellular signaling to anatomical locations of compounds.

The State of the Art in Anti-Malarial Drug Discovery and Development

2011 ◽  
Vol 999 (999) ◽  
pp. 1-29
Author(s):  
Jeremy N. Burrows ◽  
Kelly Chibale ◽  
Timothy N.C. Wells
Keyword(s):  
Drug Discovery ◽  
State Of The Art ◽  
The State ◽  
Drug Discovery And Development

Review of the Applications of Deep Learning in Bioinformatics

2021 ◽  
Vol 15 (8) ◽  
pp. 898-911
Author(s):  
Yongqing Zhang ◽  
Jianrong Yan ◽  
Siyu Chen ◽  
Meiqin Gong ◽  
Dongrui Gao ◽  
...  
Keyword(s):  
Deep Learning ◽  
Drug Discovery ◽  
Biomedical Imaging ◽  
State Of The Art ◽  
Black Box ◽  
Medical Data ◽  
Biological Data ◽  
High Dimensional ◽  
Biological Research ◽  
Process Data

Rapid advances in biological research over recent years have significantly enriched biological and medical data resources. Deep learning-based techniques have been successfully utilized to process data in this field, and they have exhibited state-of-the-art performances even on high-dimensional, nonstructural, and black-box biological data. The aim of the current study is to provide an overview of the deep learning-based techniques used in biology and medicine and their state-of-the-art applications. In particular, we introduce the fundamentals of deep learning and then review the success of applying such methods to bioinformatics, biomedical imaging, biomedicine, and drug discovery. We also discuss the challenges and limitations of this field, and outline possible directions for further research.

The State of the Art in Management Education Applicable to Aerospace Activities

1967 ◽  
Vol 71 (677) ◽  
pp. 342-343
Author(s):  
F. H. East
Keyword(s):  
Research And Development ◽  
Management Education ◽  
State Of The Art ◽  
Development Project ◽  
The State ◽  
The Other ◽  
The Past ◽  
Defence Budget ◽  
The One ◽  
Almost All

The Aviation Group of the Ministry of Technology (formerly the Ministry of Aviation) is responsible for spending a large part of the country's defence budget, both in research and development on the one hand and production or procurement on the other. In addition, it has responsibilities in many non-defence fields, mainly, but not exclusively, in aerospace.Few developments have been carried out entirely within the Ministry's own Establishments; almost all have required continuous co-operation between the Ministry and Industry. In the past the methods of management and collaboration and the relative responsibilities of the Ministry and Industry have varied with time, with the type of equipment to be developed, with the size of the development project and so on. But over the past ten years there has been a growing awareness of the need to put some system into the complex business of translating a requirement into a specification and a specification into a product within reasonable bounds of time and cost.

The State of the Art in Anti-Malarial Drug Discovery and Development

2011 ◽  
Vol 11 (10) ◽  
pp. 1226-1254 ◽  
Author(s):  
Jeremy N. Burrows ◽  
Kelly Chibale ◽  
Timothy N.C. Wells
Keyword(s):  
Drug Discovery ◽  
State Of The Art ◽  
The State ◽  
Drug Discovery And Development

Trends underlying early-stage drug discovery and development collaborations from October 2002 to September 2004

2005 ◽  
Vol 11 (4) ◽  
Author(s):  
Mark J Belsey ◽  
Alex K Pavlou
Keyword(s):  
Drug Discovery ◽  
Early Stage ◽  
Target Identification ◽  
New Wave ◽  
Fully Integrated ◽  
Drug Discovery And Development ◽  
The Past ◽  
Initial Stage ◽  
Increasing Demand

As part of Datamonitor's alliance and licensing strategic analysis, the authors have completed a two year survey of the trends underlying early-stage drug discovery and development collaborations between October 2002 and September 2004, which included 524 early-stage deals. Deal analysis shows that the leading pharma and biotech companies (fully integrated players) are the principal collaboration seekers, and that target and product innovation is driving the new wave of 21st century deals. These deals cover all phases of early-stage drug development, with lead product/target identification/validation accounting for the greatest proportion of collaborations. This represents a shift away from initial-stage collaborations, which are primarily focused on technologies such as genomics, as a result of the lack of tangible results that such technologies have delivered in the past. Following the continuously increasing demand for late-stage high-value products, the aim of the money and time invested in these early-stage collaborations is to reverse the pipeline productivity crisis currently affecting the industry's leaders over the mid to long term.

The importance of synthetic chemistry in the pharmaceutical industry

Science ◽  
2019 ◽  
Vol 363 (6424) ◽  
pp. eaat0805 ◽  
Author(s):  
Kevin R. Campos ◽  
Paul J. Coleman ◽  
Juan C. Alvarez ◽  
Spencer D. Dreher ◽  
Robert M. Garbaccio ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Synthetic Methods ◽  
Past Century ◽  
Synthetic Chemistry ◽  
Drug Discovery And Development ◽  
The Past ◽  
New Concepts ◽  
The Face ◽  
Chemical Matter

Innovations in synthetic chemistry have enabled the discovery of many breakthrough therapies that have improved human health over the past century. In the face of increasing challenges in the pharmaceutical sector, continued innovation in chemistry is required to drive the discovery of the next wave of medicines. Novel synthetic methods not only unlock access to previously unattainable chemical matter, but also inspire new concepts as to how we design and build chemical matter. We identify some of the most important recent advances in synthetic chemistry as well as opportunities at the interface with partner disciplines that are poised to transform the practice of drug discovery and development.

scholarly journals Ferrielectricity in DyMn2O5: A golden touchstone for multiferroicity of RMn2O5 family

2015 ◽  
Vol 05 (02) ◽  
pp. 1530003 ◽  
Author(s):  
J.-M. Liu ◽  
S. Dong
Keyword(s):  
Spin Structure ◽  
Structural Model ◽  
State Of The Art ◽  
Electric Polarization ◽  
Experimental Check ◽  
Spin Frustration ◽  
Temperature Dependent ◽  
The Past ◽  
Almost All ◽  
External Stimuli

The RMn 2 O 5 manganite compounds represent one class of multiferroic family with magnetic origins, which has been receiving continuous attention in the past decade. So far, our understanding of the magnetic origins for ferroelectricity in RMn 2 O 5 is associated with the nearly collinear antiferromagnetic structure of Mn ions, while the exchange striction induced ionic displacements are the consequence of the spin frustration competitions. While this scenario may be applied to almost all RMn 2 O 5 members, its limitation is either clear: the temperature-dependent behaviors of electric polarization and its responses to external stimuli are seriously materials dependent. These inconsistences raise substantial concern with the state-of-the-art physics of ferroelectricity in RMn 2 O 5. In this mini-review, we present our recent experimental results on the roles of the 4f moments from R ions which are intimately coupled with the 3d moments from Mn ions. DyMn 2 O 5 is a golden figure for illustrating these roles. It is demonstrated that the spin structure accommodates two nearly collinear sublattices which generate respectively two ferroelectric (FE) sublattices, enabling DyMn 2 O 5 an emergent ferrielectric (FIE) system rarely identified in magnetically induced FEs. The evidence is presented from several aspects, including FIE-like phenomena and magnetoelectric responses, proposed structural model, and experimental check by nonmagnetic substitutions of the 3d and 4f moments. Additional perspectives regarding possible challenges in understanding the multiferroicity of RMn 2 O 5 as a generalized scenario are discussed.

scholarly journals Pharmacogenomics of antidepressant treatment effects

2011 ◽  
Vol 13 (1) ◽  
pp. 63-71 ◽  
Keyword(s):  
Drug Discovery ◽  
Major Depression ◽  
Critical Appraisal ◽  
State Of The Art ◽  
Antidepressant Treatment ◽  
Clinical Applications ◽  
The Past ◽  
Body Of Knowledge ◽  
Tremendous Progress ◽  
Novel Targets

There has been considerable promise and hope that pharmacogenomics will optimize existing treatments for major depression, as well as identify novel targets for drug discovery. Immediately after the sequencing of the human genome, there was much hope that tremendous progress in pharmacogenomics would rapidly be achieved. In the past 10 years this initial enthusiasm has been replaced by a more sober optimism, as we have gone a long way towards the goal of guiding therapeutics based on genomics. While the effort to translate discovery to clinical applications is ongoing, we now have a vast body of knowledge as well as a clear direction forward. This article will provide a critical appraisal of the state of the art in the pharmacogenomics of depression, both in terms of pharmacodynamics and pharmacokinetics.

scholarly journals Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives

2022 ◽  
Vol 74 (1) ◽  
pp. 141-206
Author(s):  
Sonia Youhanna ◽  
Aurino M. Kemas ◽  
Lena Preiss ◽  
Yitian Zhou ◽  
Joanne X. Shen ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Human Tissue ◽  
State Of The Art ◽  
Future Perspectives ◽  
Drug Discovery And Development ◽  
Current State ◽  
Tissue Models
Sign in / Sign up

Export Citation Format

Share Document